Myrup B, Jensen G F, McNair P
Department of Clinical Chemistry, Frederiksberg Hospital, Copenhagen, Denmark.
Arch Intern Med. 1992 Nov;152(11):2265-8.
The effect of cholecalciferol and estrogen-norethindrone treatment on total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index was investigated in 74 postmenopausal women in a double-blind, randomized trial. Blood pressure and body mass index did not change throughout the study. We demonstrated a decrease (11%) in serum cholesterol level after 1 year of treatment with estrogen-norethindrone. When this treatment was combined with cholecalciferol, a similar decrease (13%) was observed. The hypocholesterolemic effect was correlated to body mass index in a way that indicated the most pronounced decrease in lean women. The high-density lipoprotein cholesterol/total cholesterol fraction increased by 45% after 1 year of estrogen-norethindrone treatment, while an increase of 25% after 1 year was seen when cholecalciferol was added to the treatment. The latter increase was not different from a similar increase in the placebo group. The possible dyslipidemic effect of cholecalciferol, along with the risk of hypercalcemia, emphasizes the caution necessary in cholecalciferol treatment.
在一项双盲随机试验中，对74名绝经后女性研究了胆钙化醇与雌激素 - 炔诺酮治疗对总胆固醇水平、高密度脂蛋白胆固醇水平、血压和体重指数的影响。在整个研究过程中，血压和体重指数没有变化。我们证明，接受雌激素 - 炔诺酮治疗1年后，血清胆固醇水平下降了11%。当这种治疗与胆钙化醇联合使用时，观察到类似程度的下降（13%）。降胆固醇作用与体重指数相关，表明瘦女性的下降最为明显。接受雌激素 - 炔诺酮治疗1年后，高密度脂蛋白胆固醇/总胆固醇比例增加了45%，而在治疗中添加胆钙化醇时，1年后增加了25%。后一种增加与安慰剂组的类似增加没有差异。胆钙化醇可能的血脂异常作用以及高钙血症风险，强调了胆钙化醇治疗时需要谨慎。
